Sociedad Americana de Hirudoterapia

Purification and properties of a coagulant thrombin-like enzyme from the venom of Bothrops leucurus

Research article published in Comparative biochemistry and physiology Part A Molecular & integrative physiology (2006)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportDesarrollo de fármacosMagalhaes A et al. · Comparative biochemistry and physiology Part A Molecular & integrative physiology, 2006

Abstract

A thrombin-like enzyme from Bothrops leucurus venom, named leucurobin (leuc), was purified by gel filtration, affinity and ion exchange chromatographies. Physicochemical studies indicated that the purified enzyme is a 35 kDa monomeric glycoprotein on SDS-PAGE under reducing conditions, which decreased to 29 kDa after deglycosylation with N-glycosidase F (PNGase F). The amino acid sequence of leuc was determined by automated sequencing of the intact native protein and peptides produced by digestion of the S-pyridyl-ethylated protein with trypsin. The protein sequence exhibits significant similarities with other serine proteases reported from snake venoms, and contains two potential sites of N-linked glycosylation. The proteinase split off fibrinopeptide A (FPA) rapidly from human fibrinogen; however, only negligible traces of fibrinopeptide B (FPB) were observed. In addition, the enzyme released the N-terminal peptide (Mr=4572) containing the first 42 residues from the Bbeta-chain. Leuc could neither activate factor XIII nor release kinins from heat-treated bovine plasma. Its specific clotting activity was equivalent to 198 NIH thrombin U/mg on human fibrinogen. Kinetic properties of leuc were determined using representative chromogenic substrates. The enzyme evoked the gyroxin syndrome when injected into the tail veins of mice at levels of 0.143 microg/g mouse. The inhibitory effects of PMSF and benzamidine on the amidolytic activity suggest that leuc is a serine proteinase, and inhibition by beta-mercaptoethanol revealed the important role of the disulfide bonds in the stabilization of the native structure. Antibothropic serum, SBTI and EDTA had little or no effect on its amidolytic activity. However, the clotting effect of the enzyme was strongly inhibited by antibothropic serum. A Dixon plot showed that the hydrolysis of Bz-L-Arg-pNA by leuc was competitively inhibited by benzamidine (Ki=1.61+/-0.25 mM).

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAmino Acid SequenceAnimalsBlood CoagulationBothropsCattleCoagulantsCrotalid VenomsFactor XIIIFibrin Fibrinogen Degradation ProductsHumansHydrolysisKinetics

Resumen

Purification and properties of a coagulant thrombin-like enzyme from the venom of Bothrops leucurus.

Por qué esto importa para la hirudoterapia

This study detailed the purification and biochemical characterization of leucurobin, a new coagulant thrombin-like serine protease derived from Bothrops leucurus snake venom. The abstract outlines the enzyme's physicochemical properties, its amino acid sequence, and its specific mechanism of cleaving fibrinopeptide A from human fibrinogen to induce clotting without activating factor XIII. Although it characterizes a thrombin-like enzyme that directly affects blood coagulation, this protein is a snake venom toxin rather than a naturally occurring component of the leech secretome. Consequently, the study offers no practical or direct relevance to clinical hirudotherapy and medical leech applications.

Citación

Purification and properties of a coagulant thrombin-like enzyme from the venom of Bothrops leucurus

Magalhaes A et al. · Comparative biochemistry and physiology Part A Molecular & integrative physiology, 2006

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.